Skip to main navigation Skip to search Skip to main content

Balancing benefit and risk of medicines: a systematic review and classification of available methodologies

  • Shahrul Mt-Isa
  • , Christine E Hallgreen
  • , Nan Wang
  • , Torbjörn Callréus
  • , Georgy Genov
  • , Ian Hirsch
  • , Stephen F Hobbiger
  • , Kimberley S Hockley
  • , Davide Luciani
  • , Lawrence D Phillips
  • , George Quartey
  • , Sinan B Sarac
  • , Isabelle Stoeckert
  • , Ioanna Tzoulaki
  • , Alain Micaleff
  • , Deborah Ashby
  • , IMI-PROTECT benefit-risk participants
  • , Tjeerd van Staa

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: The need for formal and structured approaches for benefit-risk assessment of medicines is increasing, as is the complexity of the scientific questions addressed before making decisions on the benefit-risk balance of medicines. We systematically collected, appraised and classified available benefit-risk methodologies to facilitate and inform their future use.

METHODS: A systematic review of publications identified benefit-risk assessment methodologies. Methodologies were appraised on their fundamental principles, features, graphical representations, assessability and accessibility. We created a taxonomy of methodologies to facilitate understanding and choice.

RESULTS: We identified 49 methodologies, critically appraised and classified them into four categories: frameworks, metrics, estimation techniques and utility survey techniques. Eight frameworks describe qualitative steps in benefit-risk assessment and eight quantify benefit-risk balance. Nine metric indices include threshold indices to measure either benefit or risk; health indices measure quality-of-life over time; and trade-off indices integrate benefits and risks. Six estimation techniques support benefit-risk modelling and evidence synthesis. Four utility survey techniques elicit robust value preferences from relevant stakeholders to the benefit-risk decisions.

CONCLUSIONS: Methodologies to help benefit-risk assessments of medicines are diverse and each is associated with different limitations and strengths. There is not a 'one-size-fits-all' method, and a combination of methods may be needed for each benefit-risk assessment. The taxonomy introduced herein may guide choice of adequate methodologies. Finally, we recommend 13 of 49 methodologies for further appraisal for use in the real-life benefit-risk assessment of medicines.

Original languageEnglish
Pages (from-to)667-78
Number of pages12
JournalPharmacoepidemiology and Drug Safety
Volume23
Issue number7
DOIs
Publication statusPublished - Jul 2014

Bibliographical note

Copyright © 2014 John Wiley & Sons, Ltd.

Keywords

  • review
  • benefit–risk
  • decision-making
  • medicines

Fingerprint

Dive into the research topics of 'Balancing benefit and risk of medicines: a systematic review and classification of available methodologies'. Together they form a unique fingerprint.

Cite this